RxDoctor Payments Data

Karin Hawkins, MD

Cardiovascular Disease · Baton Rouge, LANPI 1144356619

Payments from drug & device makers

$6,796in general payments, 2019–2025

Across 430 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Amgen$1K
  • Johnson & Johnson$833
  • Boehringer Ingelheim$560
  • Pfizer$543
  • Kowa Pharmaceuticals America, Inc.$429
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,782100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,796 in reported general payments places this provider in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$123,538
Medicare patients
462
Services billed
2,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban846$844,603
JardianceEmpagliflozin288$318,242
EntrestoSacubitril/Valsartan284$312,407
XareltoRivaroxaban295$309,744
Repatha SureclickEvolocumab365$258,124
FarxigaDapagliflozin Propanediol39$36,719
Praluent PenAlirocumab44$32,816
NexletolBempedoic Acid36$30,743
NexlizetBempedoic Acid/Ezetimibe34$23,153
BrilintaTicagrelor46$21,974
VascepaIcosapent Ethyl28$15,274
Repatha SyringeEvolocumab15$13,568
Metoprolol Succinate968$10,939
Atorvastatin Calcium924$6,782
Rosuvastatin Calcium510$6,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$543$844,603846 claims
Boehringer IngelheimJardiance$560$318,242288 claims
NovartisEntresto$1,363$312,407284 claims
Johnson & JohnsonXarelto$833$309,744295 claims
AstraZenecaFarxiga, Brilinta$93$58,69385 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$18$53,89570 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →